Search

Displaying results 1871 - 1880 of 7687 in total
  1. Drug

    Chorionic Gonadotropin (Human)

    go.drugbank.com/drugs/DB09126
    ApprovedInvestigationalVet approved

    HCG is composed of an alpha and a beta sub-unit.

    Products: Apl Inj 1000 Iu/ml, PREGNYL INJECTION 5000 IU
  2. Drug

    Auranofin

    go.drugbank.com/drugs/DB00995
    ApprovedInvestigational

    Heme oxygenase 1 is an inducible heme-degrading enzyme with anti-inflammatory properties.

    Synonyms: (1-Thio-beta-D-glucopyranosato)(triethylphosphine)gold 2,3,4,6-tetraacetate, 2,3,4,6-Tetra-O-acetyl-1-thio-beta-D-glucopyranosato-S (triethylphosphine)gold
  3. Drug

    Tasimelteon

    go.drugbank.com/drugs/DB09071
    ApprovedInvestigational

    Tasimelteon is currently the only drug available for the treatment of N24HSWD and was granted orphan drug status by the FDA in 2010. … In blind individuals, a lack of light stimulation causes an extension of the 24-hour circadian cycle and can lead to progressively delayed sleep onset.

  4. Drug

    Methscopolamine bromide

    go.drugbank.com/drugs/DB00462
    Approved

    A muscarinic antagonist used to study binding characteristics of muscarinic cholinergic receptors.

  5. Drug

    Deucravacitinib

    go.drugbank.com/drugs/DB16650
    ApprovedInvestigational

    [A246943] Deucravacitinib was first approved by the FDA in September 2022 to treat moderate-to-severe plaque psoriasis. … [A246938, A246943] This selectivity towards TYK2 may lead to an improved safety profile of deucravacitinib, as nonselective JAK inhibitors are associated with a range of adverse effects such as altered

  6. Drug

    Prademagene zamikeracel

    go.drugbank.com/drugs/DB17895
    ApprovedInvestigational

    [L53013] It was granted an Orphan Drug designation by the EMA.[A273833] … [L53008] Prademagene zamikeracel was first approved by the FDA on April 29, 2025, for the treatment of recessive dystrophic epidermolysis bullosa (RDEB), a skin disorder associated with excessive blistering

  7. Drug

    Pentamidine

    go.drugbank.com/drugs/DB00738
    ApprovedInvestigational

    Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of pneumocystis pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other t...

  8. Drug

    Agalsidase beta

    go.drugbank.com/drugs/DB00103
    ApprovedInvestigational

    [A220343] Agalsidase beta was granted FDA approval on 24 April 2003.[L16383] … While patients generally do not experience a clinically significant difference in outcomes between the two drugs, some patients may experience greater benefit with agalsidase beta.

  9. Drug

    Tarlatamab

    go.drugbank.com/drugs/DB17256
    ApprovedInvestigational

    [L50743] Tarlatamab-dlle was approved by the FDA in May 2024 for use in patients who have failed previous round of platinum-based chemotherapy,[L50743,L50748] becoming the first DLL3-targeting bispecific … [L50748] It is a bispecific monoclonal antibody that targets CD3 expressed on the surface of T-cells and delta-like ligand 3 (DLL3), an inhibitory ligand that suppresses Notch signaling and is highly expressed

  10. Drug

    Cysteamine

    go.drugbank.com/drugs/DB00847
    ApprovedInvestigational

    [L15611] On August 25th 2020, the first ophthalmic solution for cystinosis requiring only 4 daily treatments was granted FDA approval. … [L15606,L15616] In particular, cystine deposits on the eye can cause significant discomfort throughout the day and require frequent treatment with eye drops, typically every waking hour.